Develops a bioartificial liver device, HepaLife, to treat liver failure using a patented PICM-19 liver stem cell line; and testing platforms to improve the evaluation of drug toxicity and side effects
Donna A. Lopolito, CFO
Shawn P. Cain, director-product development
Richard E. Kruger, director-regulatory affairs
Hepalife Technologies Inc.